Storyboard

CRISPR Therapy and Its Revolutionary Impact on Healthcare, Explained

The world's first treatment that uses CRISPR gene-editing technology has been approved. Exa-cel, also known by its brand name Casgevy, received its first regulatory approval on Nov. 16, 2023 from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to treat two debilitating blood disorders: sickle cell disease and transfusion-dependent beta-thalassemia.

Avatar - Live Science
Curated by
Live Science
    • Biotechnology
    • Life Sciences
    • Genetics
    • DNA
    • Cell Biology
CRISPR Therapy and Its Revolutionary Impact on Healthcare, Explained
Continue to read
5 stories in this Storyboard
    The world's 1st CRISPR therapy has been approved. Here's everything you need to know

    The world's 1st CRISPR therapy has been approved. Here's everything you need to know

    Drug regulators have approved a CRISPR therapy called Casgevy to treat inherited blood disorders. But what is it and how does it work? The world's …

Related articles

More stories from Biotechnology